Trial Profile
Cohort Study to Explore the Therapeutic Effect of Lenvatinib on Differentiated Thyroid Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2020
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms COLLECT
- 15 Jun 2020 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 14 May 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2016 Status changed from not yet recruiting to recruiting.